The Sodium Pump: Bridging the Basic and Clinical Cardiovascular Sciences

Author(s): Donald M. Foster, Suresh K. Verma, Hind Lal, John C. Reneau, Manuela Smith, David E. Dostal

Journal Name: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Continued as New Advances on Endocrine Metabolic and Immune Diseases

Volume 1 , Issue 3 , 2007


Year 2007 is the golden anniversary for the discovery of the sodium- and potassium adenosine triphosphatase, i.e., Na+, K+-ATPase, or Na+-pump by Jens Skou who shared the 1997 Nobel Prize in Chemistry for his discovery. Prior to identification of the enzymatic basis of Na+ and K+ active transport by Skou, the physiological and pharmacological manifestations of such a system had long been evident. Since 1957, there has been a dramatic increase in the knowledge of the physical, chemical, and kinetic properties of the pump and recognition of its basis for a wide range of physiological, pathological, and pharmacological aspects of the cardiovascular system. The Na+-pump has recently been identified as a key partner in a wide array of cell signaling pathways related to hypertrophy and expression of its marker genes. Taken together, these facts make it evident that the pump is a prime target for pharmacological interventions of cardiovascular diseases such as hypertrophy, hypertension, congestive heart failure (CHF), and preeclampsia. This review couples basic attributes of the Na+-pump with pathophysiological etiologies and clinical management of cardiovascular related maladies, and also discusses related patents.

Keywords: Cardiac glycosides, ouabain, marinobufagenin, Na+, K+-ATPase, sodium pump, signal transduction

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [224 - 246]
Pages: 23
DOI: 10.2174/187221407782409099
Price: $58

Article Metrics

PDF: 3